Clinical Trials Logo

Hemoglobinuria clinical trials

View clinical trials related to Hemoglobinuria.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT06028594 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria

Start date: n/a
Phase:
Study type: Expanded Access

This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare immune disease that causes red blood cells in your body to break apart.

NCT ID: NCT05982938 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Danicopan Early Access Program

Start date: n/a
Phase:
Study type: Expanded Access

This is an EAP, designed to provide early access to danicopan for participants with PNH experiencing clinically significant EVH who have failed, not tolerated, or are unable to receive other approved treatments; in the Treating Physician's opinion, the participant is not eligible for or is not able to participate in an ongoing clinical trial of danicopan or a comparable treatment; and according to the Treating Physician, the benefit of danicopan treatment outweighs the potential risks.

NCT ID: NCT05222412 Available - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria (PNH)

Managed Access Programs for LNP023, Iptacopan

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan